Announcement: We updated MyCEI, the CEI learning management portal. Available online now! For any question contact us at: support@ceitraining.org
/-->Menu
Search
Home > Courses > HIV Drug Resistance: A Reassessment

HIV Drug Resistance: A Reassessment

HIV Drug Resistance: A Reassessment
Play
Sorry, this learning module is not available for mobile devices.
Original Release Date: 10/17/2017
Termination Date: 10/16/2020
Review Date: 1/12/2018
Presenter
  • Daniel R Kuritzkes, MD
    Professor
    Harvard Medical School
Learning Objectives / Desired Outcomes
At the completion of this educational activity, participants will:
  1. Understand the current epidemiology of transmitted drug resistance.
  2. Know the risks of drug resistance in patients receiving PrEP.
  3. Appreciate the impact of transmitted resistance on response to current first-line ART.
Presenter Bio
Daniel Kuritzkes, MD
Daniel R. Kuritzkes received his BS and MS degrees in Molecular Biophysics and Biochemistry from Yale University, and his MD from Harvard Medical School. He completed his clinical and research training in internal medicine and infectious diseases at Massachusetts General Hospital and was a visiting scientist at the Whitehead Institute for Biomedical Research before joining the faculty at the University of Colorado Health Sciences Center. Dr. Kuritzkes returned to Harvard Medical School in 2002, where he is Professor of Medicine and Chief, Division of Infectious Diseases at Brigham and Women’s Hospital. Dr. Kuritzkes has published extensively on antiretroviral therapy and drug resistance in HIV-1 infection, has chaired several multicenter studies of HIV therapy, and currently serves as Principal Investigator and Chair of the AIDS Clinical Trials Group. He is a member of the NIH Office of AIDS Research Advisory Council, and serves as an Associate Editor of the Journal of Infectious Diseases. He is a former member of the Department of Health and Human Services panel on guidelines for antiretroviral therapy and a past Chair of the HIV Medicine Association Board of Directors. His research interests focus on antiretroviral therapy, drug resistance and HIV eradication.
Continuing Education Credit

This CME activity was approved for AMA PRA Category 1 Credit™ on October 17, 2017 and will terminate October 16, 2020.

The target audience is all physicians, NPs and PAs involved or interested in HIV education.

This online video and post-activity evaluation are one hour in length.

  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
  • You must achieve at least 70% correct to receive your CME certificate.
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.

 Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with extent of their participation in the activity.

Disclosure Statement 

Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.  

  • Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
  • Dr. Kuritzkes (Presenter) had the following personal financial relationships in the prior 12 months with manufacturers of the products or services that may be presented in this CME activity: Consultant to Gilead, Merck, Janssen, and ViiV; Research Support from Gilead, Merck, and ViiV; Speaker for Gilead. Dr. Kuritzkes submitted his slides in advance for adequate peer review, and will support his presentation and clinical recommendations with the best available evidence from the medical literature.

Financial Support

This meeting of the Physicians' Research Network (PRN) and enduring material were funded in part by educational grants from: Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, Merck & Co, and ViiV Healthcare.

Details:

  • This online video and post-activity evaluation are one hour in length. 
  • After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz. 
  • You must achieve at least 70% correct to receive your CME certificate. 
  • If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
PRN Learning Modules